Πέμπτη 2 Νοεμβρίου 2017

Uncoupling the Oncogenic Engine

Inhibition of oncogenic signaling and correction of aberrant metabolic processes may be key paradigms to eliminate cancer cells. The high incidence of activating RAS mutations and hyperactivated ERK1/2 signaling observed in many human tumors and the lack of effective targeted therapies to elicit long-term inhibition of the RAS-ERK1/2 signaling pathway add to the importance of discovering novel strategies to treat malignancies characterized by elevated RAS-ERK1/2 signaling. In this review, we describe connections between oncogenic signaling and cancer cell metabolism and how these links may be exploited for novel modern molecular medicine approaches. Cancer Res; 77(22); 1–5. ©2017 AACR.

http://ift.tt/2yoTcpQ

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου